Changes of bone mineral density after 2-yrs treatment with HRT and alendronate in osteoporotic Korean women.
- Author:
Han Jin OH
1
;
Sang Man KIM
;
Dong Hee CHO
;
Hyun Koo YOON
;
In Kwon HAN
Author Information
1. Department of Family Medicine, Samsung Cheil Hospital & Women's Health Care Center Sungkyunkwan University, School of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
postmenopause;
osteoporosis;
Korean women;
alendronate;
HRT;
bone marker
- MeSH:
Alendronate*;
Bone Density*;
Breast;
Case-Control Studies;
Climacteric;
Female;
Humans;
Osteoporosis;
Patient Dropouts;
Postmenopause;
Spine;
Uterine Hemorrhage;
Women's Health
- From:Journal of the Korean Academy of Family Medicine
2002;23(4):475-484
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Alendronate is one of the anti-resorptive drugs for the treatment of osteoporosis and results in a decrease of bone turnover. HRT is also known to decrease the bone turnover. Combination therapy with HRT and alendronate has made significant increase of BMD in postmenopausal women. But there were no available long-term results about combination therapy of HRT and alendronate on Korean osteoporotic women. METHODS: Eighty postmenopausal women with osteoporosis who visited the Climacteric clinic in Samsung Cheil Hospital & Women's Health Care Center from Apil to July 1999 were subjects. Randomized open labeled case control study was made. We evaluated 37 postmenopausal osteoporotic Korean women who were treated for 2 years after enrollment. Subjects in Group I were treated with HRT only, and group II had HRT with alendronate 10 mg daily. Subjects also were measured BMD at lumbar spine and markers of bone turnover before, one and two year after treatment. RESULTS: Common reasons for dropouts were side effects of HRT such as breast tenderness, irregular vaginal bleeding, economic problems, long distance from clinic etc. BMD in lumbar spine was increased 10.1% in the first year, and 12.0% in the second year in subjects treated with HRT and alendronate. But in HRT only group BMD increased to 6.4% in the first year and 7.8% at second year. Markers of bone turnover were decreased significantly in both groups compared with baseline value, but the percent changes of markers after 1 year and 2 years between the two groups were not significant. CONCLUSION: This study demonstrated that, in postmenopausal Korean women with osteoporosis, 2 years of combination therapy with HRT and alendronate resulted in a significant and sustained increase in spinal BMD than HRT only group.
